BridgeBio Pharma (BBIO) Net Margin (2019 - 2026)

BridgeBio Pharma has disclosed Net Margin across 8 years of filings, most recently posting 84.33% for Q1 2026.

• Net Margin for Q1 2026 came in at 84.33%, up 5921.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 124.41% (up 39983.0% YoY), and the FY2025 annual result was 144.39%, up 9705.0% from the prior year.
• Net Margin came in at 84.33% for Q1 2026 at BridgeBio Pharma, up from 125.09% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 13.36% in Q2 2022 to a low of 40632.84% in Q3 2022.
• The 5-year median for Net Margin is 4326.55% (2023), against an average of 6198.18%.
• Across the five-year window, Net Margin slumped 3398032 bps in 2022 and surged 3630629 bps in 2023, its largest moves.
• BridgeBio Pharma's Net Margin stood at 7357.81% in 2022, then sank by 31 bps to 9635.99% in 2023, then jumped by 53 bps to 4506.12% in 2024, then jumped by 97 bps to 125.09% in 2025, then surged by 33 bps to 84.33% in 2026.
• The last three Net Margin figures came in at 84.33% (Q1 2026), 125.09% (Q4 2025), and 151.4% (Q3 2025), per Business Quant data.